Skip to main content

Advertisement

SpringerLink
Log in

Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The study was aimed to explore the efficacy and safety of allo-HSCT with high-dose cyclophosphamide-induced immune tolerance for SAA. In the present study, 20 cases (12 male, 8 female; average age = 17.8 years) received reduced-intensity conditioning allo-HSCT from August 2012 to August 2014 in the Beijing Military Region General Hospital. All were HLA mismatched and received CSA; 11 received ATG-intensive immune therapy. Donors underwent mobilization with cell colony-stimulating factor. The modified preconditioning regimen included reduced-strength fludarabine combined with Busulfex and cytarabine, cyclophosphamide. Cyclophosphamide (50 mg/kg/d) induced immune tolerance 3 days after transplantation and was combined with immunosuppressive agents, including CSA, MTX, and FK506, for GVHD prophylaxis and the management of observed toxicity, GVHD and DFS. Hematopoietic reconstitution was achieved in 17 cases and engraftment after a second transplantation in an additional three cases. The average times to engraftment were 17.4 and 21.3 days, respectively, with neutrophils ≥0.5 × 109/L and platelets ≥20 × 109/L. Engraftment was confirmed by the evidence of 100 % donor hematopoiesis; T lymphocyte subset counts also increased significantly after transplantation. During follow-up monitoring to April 2015 (median duration = 17.7 months), three patients died of complications, while the other 17 showed disease-free survival (DFS rate = 85 %; longest DFS period = 32 months). Reduced-intensity allo-HSCT with high-dose cyclophosphamide-induced immune tolerance treatment is effective for SAA and can be the key technology extensively used in clinic, but its efficacy needs to be confirmed further with prospective randomized study with increased sample size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jaime-Pérez JC, Colunga-Pedraza PR, Gómez-Ramírez CD, Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Tarín-Arzaga LC, et al. Danazol as first-line therapy for aplastic anemia [J]. Ann Hematol. 2011;90(5):523–7.

    Article  PubMed  Google Scholar 

  2. Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor vs immunosuppressive therapy [J]. Haematologica. 2014;99(12):1784–91.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wang M, Li X, Shi J, Shao Y, Ge M, Huang J, et al. Outcome of a novel immunosuppressive strategy of cyclosporine, levamisole and danazol for severe aplastic anemia [J]. Int J Hematol. 2015;102(2):149–56.

    Article  CAS  PubMed  Google Scholar 

  4. Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study [J]. Bone Marrow Transplant. 2015;50(5):685–9.

    Article  CAS  PubMed  Google Scholar 

  5. Fu Y, Wang Q, Zhou J, Liu S, Fang B, Wei X, et al. Reduced intensity conditioning and co-transplantation of unrelated peripheral stem cells combined with umbilical cord mesenchymal stem/stroma cells for young patients with refractory severe aplastic anemia [J]. Int J Hematol. 2013;98(6):658–63.

    Article  PubMed  Google Scholar 

  6. Szpecht D, Gorczyńska E, Kałwak K, Owoc-Lempach J, Choma M, Styczyński J, et al. Matched sibling vs matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia:experience of the polish pediatric group for hematopoietic stem cell transplantation [J]. Arch Immunol Ther Exp (Warsz). 2012;60(3):225–33.

    Article  Google Scholar 

  7. Wang S, Chen Y, Zou Y, Zheng Y, Zhu X. The progression risk factors of children with transfusion-independent non-severe aplastic anemia [J]. Int J Hematol. 2013;97(2):210–5.

    Article  CAS  PubMed  Google Scholar 

  8. Lee YH, Kim JY, Choi BO, Ryu MR, Chung SM. Total lymphoid irradiation based conditioning for hematopoietic stem cell transplantation in severe aplastic anemia [J]. Radiat Oncol J. 2012;30(4):165–72.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pillai A, Hartford C, Wang C, Pei D, Yang J, Srinivasan A, et al. Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia [J]. Pediatr Transplant. 2011;15(6):628–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, et al. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation [J]. Am J Hematol. 2013;88(4):294–300.

    Article  CAS  PubMed  Google Scholar 

  11. Vajdic CM, Mayson E, Dodds AJ, O’Brien T, Wilcox L, Nivison-Smith I, et al. Second cancer risk and late mortality in adult Australians receiving allogeneic hematopoietic stem cell transplantation: a population-based cohort study [J]. Biol Blood Marrow Transplant. 2016;22(5):949–56.

    Article  PubMed  Google Scholar 

  12. Velázquez-Sánchez-de-Cima S, Zamora-Ortiz G, Hernández-Reyes J, Rosales-Durón AD, González-Ramírez MP, Martagón-Herrera NA, et al. Oral vs intravenous fludarabine as part of a reduced-intensity conditioning for allogeneic stem cell transplantation [J]. Acta Haematol. 2014;132(1):125–8.

    Article  PubMed  Google Scholar 

  13. Hutspardol S, Essa M, Richardson S, Schechter T, Ali M, Krueger J, et al. Significant transplantation-related mortality from respiratory virus infections within the first 100 days in children after hematopoietic stem cell transplantation [J]. Biol Blood Marrow Transplant. 2015;21(10):1802–7.

    Article  PubMed  Google Scholar 

  14. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse [J]. J Clin Oncology. 2005;23(15):3447–54.

    Article  Google Scholar 

  15. Worel N, Böhm A, Rabitsch W, Leitner G, Mitterbauer M, Kalhs P, et al. Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning [J]. Transfusion. 2012;52(6):1348–53.

    Article  CAS  PubMed  Google Scholar 

  16. Fleischhauer K, Fernandez-Viña MA, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe LA, et al. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1 [J]. Bone Marrow Transplant. 2014;49(9):1176–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Jaiswal SR, Chatterjee S, Mukherjee S, Ray K, Chakrabarti S. Pre-transplant sirolimus might improve the outcome of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide for patients with severe aplastic anemia [J]. Bone Marrow Transplant. 2015;50(6):873–5.

    Article  CAS  PubMed  Google Scholar 

  18. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide [J]. Biol Blood Marrow Transplant. 2008;14(6):641–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chun C, Fang JP, Xue HM, Zhou DH, Huang K, Xu HG, et al. Allogeneic hematopoietic stem cell transplantation for childhood aplastic anemia:prospective trial in China [J]. Transfus Apher Sci. 2011;44(1):41–7.

    Article  PubMed  Google Scholar 

  20. Kim H, Kim BS, Kim DH, Hyun MS, Kim SH, Bae SH, et al. Comparison between matched related and alternative donors of allogeneic hematopoietic stem cells transplanted into adult patients with acquired aplastic anemia:multivariate and propensity score-matched analysis [J]. Biol Blood Marrow Transplant. 2011;17(9):1289–98.

    Article  PubMed  Google Scholar 

  21. Nakamae H, Koh H, Katayama T, Nishimoto M, Hayashi Y, Nakashima Y, et al. HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome [J]. Exp Hematol. 2015;43(11):921–9.

    Article  PubMed  Google Scholar 

  22. Mahmoud HK, Elhaddad AM, Fahmy OA, Samra MA, Abdelfattah RM, El-Nahass YH, et al. Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders [J]. J Adv Res. 2015;6(3):449–58.

    Article  PubMed  Google Scholar 

  23. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation [J]. Biol Blood Marrow Transplant. 2012;18(12):1835–44.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation [J]. J Clin Oncol. 2013;31(10):1310–6.

    Article  CAS  PubMed  Google Scholar 

  25. Ikegame K, Kaida K, Yoshihara S, Fujiwara M, Taniguchi K, Kato R, et al. Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients [J]. Int J Hematol. 2012;96(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  26. Kaida K, Ikegame K, Ikemoto J, Murata R, Irie R, Yoshihara S, et al. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-vs-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning [J]. Int J Hematol. 2014;99(4):463–70.

    Article  CAS  PubMed  Google Scholar 

  27. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies [J]. Blood. 2013;121(5):849–57.

    Article  PubMed  Google Scholar 

  28. Kim H, Lee KH, Yoon SS, Sohn SK, Joo YD, Kim SH, et al. Allogeneic hematopoietic stem cell transplant for adults over 40 years old with acquired aplastic anemia [J]. Biol Blood Marrow Transplant. 2012;18(10):1500–8.

    Article  PubMed  Google Scholar 

  29. Guo Z, Chen HR, Liu XD, Lou JX, Yang K, Zhang Y, et al. Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22(5):1359–64.

    CAS  PubMed  Google Scholar 

  30. Guo Z, Chen HR, Liu XD, Lou JX, Yang K, Zhang Y, et al. Clinical research of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(2):441–5.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, PLA Army General Hospital, Beijing, 100700, China

    Zhi Guo, Hong-yan Gao, Tian-yan Zhang, Xiao-dong Liu, Kai Yang, Jing-xing Lou, Xue-peng He, Yuan Zhang, Peng Chen & Hui-ren Chen

Authors
  1. Zhi Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong-yan Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tian-yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-dong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kai Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jing-xing Lou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xue-peng He
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hui-ren Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui-ren Chen.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, Z., Gao, Hy., Zhang, Ty. et al. Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia. Int J Hematol 104, 720–728 (2016). https://doi.org/10.1007/s12185-016-2106-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-016-2106-z

Keywords

Search

Navigation